期刊
MOLECULES
卷 28, 期 2, 页码 -出版社
MDPI
DOI: 10.3390/molecules28020621
关键词
drug-induced liver injury; hepatic in vitro model; hepatotoxicity; intrahepatic cholangiocyte organoids; hepatocyte-like cells
In vitro toxicity testing using hepatocyte-like intrahepatic cholangiocyte organoids (HL-ICOs) allows for the evaluation of drug metabolism gene expression and activity, providing insights into the extent of drug-induced hepatotoxicity.
Emerging advances in the field of in vitro toxicity testing attempt to meet the need for reliable human-based safety assessment in drug development. Intrahepatic cholangiocyte organoids (ICOs) are described as a donor-derived in vitro model for disease modelling and regenerative medicine. Here, we explored the potential of hepatocyte-like ICOs (HL-ICOs) in in vitro toxicity testing by exploring the expression and activity of genes involved in drug metabolism, a key determinant in drug-induced toxicity, and the exposure of HL-ICOs to well-known hepatotoxicants. The current state of drug metabolism in HL-ICOs showed levels comparable to those of PHHs and HepaRGs for CYP3A4; however, other enzymes, such as CYP2B6 and CYP2D6, were expressed at lower levels. Additionally, EC50 values were determined in HL-ICOs for acetaminophen (24.0-26.8 mM), diclofenac (475.5->500 mu M), perhexiline (9.7->31.5 mu M), troglitazone (23.1-90.8 mu M), and valproic acid (>10 mM). Exposure to the hepatotoxicants showed EC50s in HL-ICOs comparable to those in PHHs and HepaRGs; however, for acetaminophen exposure, HL-ICOs were less sensitive. Further elucidation of enzyme and transporter activity in drug metabolism in HL-ICOs and exposure to a more extensive compound set are needed to accurately define the potential of HL-ICOs in in vitro toxicity testing.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据